Xenon Announces Appointment of Ian C. Mortimer as Chief Financial Officer

Xenon Announces Appointment of Ian C. Mortimer as Chief Financial Officer 
VANCOUVER, British Columbia, Sept. 10, 2013 /CNW/ - Xenon Pharmaceuticals Inc. 
is pleased to announce the appointment of Mr. Ian C. Mortimer as Chief 
Financial Officer. 
"We are delighted to welcome Ian to the Xenon team," said Dr. Simon Pimstone, 
Xenon's President and CEO. "Ian brings a combination of strong financial and 
operations experience that is highly relevant to Xenon. Given our pipeline of 
approved, development stage and discovery stage products and programs, 
together with our strong balance sheet and our suite of major pharmaceutical 
partnerships, this is a good time for Xenon to be adding an experienced CFO 
like Ian to the company." 
Mr. Mortimer has over 15 years experience in the biotechnology sector. He is 
currently Executive Vice President and Chief Financial Officer at Tekmira 
Pharmaceuticals Corporation (Tekmira), a Nasdaq-listed biotechnology company 
focused on advancing RNAi therapeutic products.  Mr. Mortimer is responsible 
for all aspects of Tekmira's finance and capital markets activities and led 
Tekmira's listing on Nasdaq in 2010.  Prior to his most recent position at 
Tekmira, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals 
Corporation.  Mr. Mortimer has an MBA from Queen's University, a B.Sc. in 
Microbiology from the University of British Columbia and is a Certified 
Management Accountant.  Mr. Mortimer will join Xenon as Chief Financial 
Officer full time by November 1, 2013. 
About Xenon Pharmaceuticals Inc. Xenon is a privately owned biopharmaceutical 
company focused on the development of novel medicines through the application 
of our proprietary discovery platform, which we refer to as Extreme Genetics. 
We are developing proprietary product candidates for the treatment of both 
orphan as well as more prevalent diseases. For more information, visit the 
Company's website at http://www.xenon-pharma.com. 
This release contains forward-looking statements that are not based on 
historical fact. These forward-looking statements involve risks, uncertainties 
and other factors that may cause the actual results, events or developments to 
be materially different from those expressed or implied by such 
forward-looking statements. Readers are cautioned not to place undue reliance 
on such forward-looking statements.
 

SOURCE  Xenon Pharmaceuticals Inc. 
Dr. Simon Pimstone, President & CEO, +1-604-484-3300, ddunn@xenon-pharma.com 
http://www.xenon-pharma.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/September2013/10/c5659.html 
CO: Xenon Pharmaceuticals Inc.
ST: British Columbia
NI: HEA MTC BTC 2575 WNEWS  
-0- Sep/10/2013 10:05 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.